Novo Nordisk announces its intention to advance amycretine for subcutaneous and oral administration into Phase 3 development for weight management, based on completed clinical studies and feedback received from regulatory authorities.

The Danish pharmaceutical company now plans to initiate a Phase 3 development program with amycretine for overweight or obese adults in Q1 2026.

A long-acting, single-molecule agonist of GLP-1 and amylin receptors currently in development, amycretine aims to provide an effective and convenient treatment for overweight or obese adults and those with type 2 diabetes.


Copyright (c) 2025 CercleFinance.com. All rights reserved.